Study S000800

A 12-Week Phase 3 Clinical Trial to Evaluate the Safety, Tolerability and Efficacy of Tirzepatide-Assisted-Psychotherapy in Adults With Cannabis Use Disorder: A Proof-of-Concept Study

Name: LivingGLP1 adjudicated trial data and network meta-analysis results
Creator: Ahmad Sofi-Mahmudi
License: https://creativecommons.org/licenses/by/4.0/

ClinicalTrials.gov record

Registration

Registration: NCT07671248
Study type: INTERVENTIONAL
Phase: PHASE3
Masking: NONE
Status: NOT_YET_RECRUITING
Enrollment: 15
Start: 2026-08-01
Primary completion: 2028-07-31
Lead sponsor: McMaster University
Conditions: Cannabis Use Disorder, Moderate; Cannabis Use Disorder, Severe
Interventions: DRUG:Tirzepatide
Results posted: FALSE
Individual participant data sharing: UNDECIDED

Registered primary outcomes

Tolerability of Tirzepatide-Assisted-Psychotherapy for Cannabis Use Disorder. [From baseline to 12-week endpoint.]
Feasibility of Tirzepatide-Assisted-Psychotherapy for Cannabis Use Disorder. [From baseline to 12-week endpoint.]

Linked records (0)

Automatic links, confirmed or rejected during screening. A record citing this registration may be a secondary analysis, a commentary or a review that mentions the trial.

No records link to this registration yet.